Scholarlink

<p>This study explores the potential of phytochemicals as an innovative and successful strategy for mitigating symptoms of benign prostatic hyperplasia and prostate cancer. Prostate cancer is the most prevalent and second highest cause of mortality for men, with over 121 million cases worldwide. Finding no comprehensive study on the impact of compounds from all phytochemical classes in the perspectives of prostate disorders, this study analyzed data from a variety of investigations, including preclinical studies, in vitro and in vivo experiments, clinical trials, and cell line investigations, as part of a review of the literature. With a focus on mechanisms such as aging and hormonal factor modulation, apoptosis induction, overcoming inflammation, metabolic crisis, and medication resistance while minimizing side effects, the search concentrated on the effects of natural substances on prostate hyperplastic and malignant cells. The sequel of the study is suggestive of strong anti-hyperplastic and anti-cancerous potentials of phytochemicals in prostate cells. These phytochemicals have the capacity to target several pathways, providing a multifaceted approach to the therapy of BPH and prostate cancer. Interestingly, a large number of these substances exhibit negligible side effects, suggesting their possible use in clinical settings. The study unveils the mechanistic role of compounds belonging to various phytochemical classes in improving life quality and longevity in men with BPH and prostate cancer. Besides associating the existing literature, outcomes of the study ignite encouraging prospects towards further advancements in drug discovery and anticipation for prompt therapies.</p> Graphical Abstract <p>Schematic representation of phytochemical classes for their anti-BPH, anti-inflammatory, and anti-Prostate cancer actions along with associated molecular pathway modulation.</p> <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Green chemistry for prostate health: exploring nature’s toolbox against cancer, inflammation, and hyperplasia

  • 期刊论文

  • 发表日期：

    2025年8月5日

查看全文
  • Muavia Sarwar,
  • Hafiz Muhammad Irfan,
  • Alamgeer,
  • Zeeshan Jabbar,
  • Mulazim Hussain Asim,
  • Muhammad Sajjad Hassan,
  • Shoaib Nawaz

摘要

This study explores the potential of phytochemicals as an innovative and successful strategy for mitigating symptoms of benign prostatic hyperplasia and prostate cancer. Prostate cancer is the most prevalent and second highest cause of mortality for men, with over 121 million cases worldwide. Finding no comprehensive study on the impact of compounds from all phytochemical classes in the perspectives of prostate disorders, this study analyzed data from a variety of investigations, including preclinical studies, in vitro and in vivo experiments, clinical trials, and cell line investigations, as part of a review of the literature. With a focus on mechanisms such as aging and hormonal factor modulation, apoptosis induction, overcoming inflammation, metabolic crisis, and medication resistance while minimizing side effects, the search concentrated on the effects of natural substances on prostate hyperplastic and malignant cells. The sequel of the study is suggestive of strong anti-hyperplastic and anti-cancerous potentials of phytochemicals in prostate cells. These phytochemicals have the capacity to target several pathways, providing a multifaceted approach to the therapy of BPH and prostate cancer. Interestingly, a large number of these substances exhibit negligible side effects, suggesting their possible use in clinical settings. The study unveils the mechanistic role of compounds belonging to various phytochemical classes in improving life quality and longevity in men with BPH and prostate cancer. Besides associating the existing literature, outcomes of the study ignite encouraging prospects towards further advancements in drug discovery and anticipation for prompt therapies.

Graphical Abstract

Schematic representation of phytochemical classes for their anti-BPH, anti-inflammatory, and anti-Prostate cancer actions along with associated molecular pathway modulation.